Cargando…

Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients

The COVID-19 pandemic continues to be a worldwide health issue. Among hemodialysis (HD) patients, two-dose immunization schemes with mRNA vaccines have contributed to preventing severe COVID-19 cases; however, some have not produced a sufficient humoral response, and most have developed a rapid decl...

Descripción completa

Detalles Bibliográficos
Autores principales: Broseta, José Jesús, Rodríguez-Espinosa, Diana, Cuadrado, Elena, Rodríguez, Néstor, Bedini, José Luis, Maduell, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030003/
https://www.ncbi.nlm.nih.gov/pubmed/35455271
http://dx.doi.org/10.3390/vaccines10040522
_version_ 1784692037720735744
author Broseta, José Jesús
Rodríguez-Espinosa, Diana
Cuadrado, Elena
Rodríguez, Néstor
Bedini, José Luis
Maduell, Francisco
author_facet Broseta, José Jesús
Rodríguez-Espinosa, Diana
Cuadrado, Elena
Rodríguez, Néstor
Bedini, José Luis
Maduell, Francisco
author_sort Broseta, José Jesús
collection PubMed
description The COVID-19 pandemic continues to be a worldwide health issue. Among hemodialysis (HD) patients, two-dose immunization schemes with mRNA vaccines have contributed to preventing severe COVID-19 cases; however, some have not produced a sufficient humoral response, and most have developed a rapid decline in antibody levels over the months following vaccination. This observational, prospective, multi-center study evaluated the humoral response in terms of presence and levels of IgG antibodies to the receptor-binding domain of the S1 spike antigen of SARS-CoV-2 (anti-S1-RBD IgG) to the third dose of SARS-CoV-2 mRNA vaccines, either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer), in 153 patients from three dialysis units affiliated to Hospital Clínic of Barcelona (Spain). Most hemodialysis patients responded intensely to this third vaccine dose, achieving the seroconversion in three out of four non- or weak responders to two doses. Moreover, 96.1% maintained the upper limit or generated higher titers than after the second. BNT162b2 vaccine, active cancer, and immunosuppressive treatment were related to a worse humoral response. Every hemodialysis patient should be administered a third vaccine dose six months after receiving the second one. Despite the lack of data, immunosuppressed patients and those with active cancer may benefit from more frequent vaccine boosters.
format Online
Article
Text
id pubmed-9030003
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90300032022-04-23 Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients Broseta, José Jesús Rodríguez-Espinosa, Diana Cuadrado, Elena Rodríguez, Néstor Bedini, José Luis Maduell, Francisco Vaccines (Basel) Article The COVID-19 pandemic continues to be a worldwide health issue. Among hemodialysis (HD) patients, two-dose immunization schemes with mRNA vaccines have contributed to preventing severe COVID-19 cases; however, some have not produced a sufficient humoral response, and most have developed a rapid decline in antibody levels over the months following vaccination. This observational, prospective, multi-center study evaluated the humoral response in terms of presence and levels of IgG antibodies to the receptor-binding domain of the S1 spike antigen of SARS-CoV-2 (anti-S1-RBD IgG) to the third dose of SARS-CoV-2 mRNA vaccines, either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer), in 153 patients from three dialysis units affiliated to Hospital Clínic of Barcelona (Spain). Most hemodialysis patients responded intensely to this third vaccine dose, achieving the seroconversion in three out of four non- or weak responders to two doses. Moreover, 96.1% maintained the upper limit or generated higher titers than after the second. BNT162b2 vaccine, active cancer, and immunosuppressive treatment were related to a worse humoral response. Every hemodialysis patient should be administered a third vaccine dose six months after receiving the second one. Despite the lack of data, immunosuppressed patients and those with active cancer may benefit from more frequent vaccine boosters. MDPI 2022-03-27 /pmc/articles/PMC9030003/ /pubmed/35455271 http://dx.doi.org/10.3390/vaccines10040522 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Broseta, José Jesús
Rodríguez-Espinosa, Diana
Cuadrado, Elena
Rodríguez, Néstor
Bedini, José Luis
Maduell, Francisco
Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
title Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
title_full Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
title_fullStr Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
title_full_unstemmed Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
title_short Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
title_sort humoral response after three doses of mrna-1273 or bnt162b2 sars-cov-2 vaccines in hemodialysis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030003/
https://www.ncbi.nlm.nih.gov/pubmed/35455271
http://dx.doi.org/10.3390/vaccines10040522
work_keys_str_mv AT brosetajosejesus humoralresponseafterthreedosesofmrna1273orbnt162b2sarscov2vaccinesinhemodialysispatients
AT rodriguezespinosadiana humoralresponseafterthreedosesofmrna1273orbnt162b2sarscov2vaccinesinhemodialysispatients
AT cuadradoelena humoralresponseafterthreedosesofmrna1273orbnt162b2sarscov2vaccinesinhemodialysispatients
AT rodrigueznestor humoralresponseafterthreedosesofmrna1273orbnt162b2sarscov2vaccinesinhemodialysispatients
AT bedinijoseluis humoralresponseafterthreedosesofmrna1273orbnt162b2sarscov2vaccinesinhemodialysispatients
AT maduellfrancisco humoralresponseafterthreedosesofmrna1273orbnt162b2sarscov2vaccinesinhemodialysispatients